Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

DUBLIN, March 2, 2018 -- (Healthcare Sales & Marketing Network) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with standard review the company's New Drug Application (ND... Biopharmaceuticals, FDA Jazz Pharmaceuticals, solriamfetol, narcolepsy, obstructive sleep apnea
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news